Introgen Therapeutics Cancer Drugs Clinical Pipeline Insight

Publish Date:- Nov-2016       No Of Pages (33)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Introgen Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Introgen Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Introgen Therapeutics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Introgen Therapeutics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Introgen Therapeutics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there is “1” cancer drug in clinical pipeline.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Introgen Therapeutics - Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Introgen Therapeutics

  1.1 Business Overview

  1.2 Introgen Therapeutics Cancer Pipeline Overview

 

2. Introgen Therapeutics Cancer Drugs in Phase-II

  2.1 CNVN 202

 

3. No Development Reported in Cancer Drugs in Clinical Pipeline

  3.1 K-ras Gene Therapies - Introgen/sanofi-aventis

 

4. Discontinued in Cancer Drugs in Clinical Pipeline

  4.1 Contusugene Ladenovec - Gendux/Introgen

  4.2 INGN 241

  4.3 INGN 234

  4.4 Oral Cancer Therapeutics - Introgen/Colgate-Palmolive

  4.5 Tumour Suppressing Gene Therapies - Introgen

  4.6 Oncolytic Viruses - Introgen

  4.7 BAK Gene Therapies - Introgen

  4.8 p16 Gene Therapies - Introgen

  4.9 Anti-Ras Antibody Gene Therapy

  4.10 INGN 231

  4.11 INGN 212

  4.12 INGN 251

  4.13 Mebendazole


Figure 1-1: Introgen Therapeutics Cancer Pipeline by Phase (%)

Figure 1-2: Introgen Therapeutics Cancer Pipeline by Phase (Number)